MMSI:NSD-Merit Medical Systems, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 45.21

Change

-0.44 (-0.96)%

Market Cap

USD 2.34B

Volume

0.38M

Average Target Price

USD 46.82 (+3.56%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, interventional fluid management, pressure monitoring, and cardiac rhythm management, as well as thermodilution and pulmonary artery catheters and electrophysiology to treat various heart conditions. It also offers cardiovascular and critical care products to treat patients with life-threatening diseases, and protect healthcare providers from exposure to bloodborne pathogens. In addition, it provides interventional oncology and spine products to treat vertebral compression fractures, metastatic spinal tumors, liver cancer, uterine fibroids, benign prostatic hyperplasia, vertebral compression fractures, and arteriovenous malformations and hemostatic embolization, as well as breast cancer localization and guidance products for the treatment of breast cancer. Further, it offers non-vascular stents to treat pulmonary and gastrointestinal diseases; dilation balloons to endoscopically dilate strictures; and kits and accessories for endoscopy and bronchoscopy procedures. Additionally, it provides coated tubes and wires; microelectromechanical system sensor components; ConvertX nephroureteral stent system; and Fibrovein, a detergent-based sclerosant. The company sells its products to hospitals and clinic-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was founded in 1987 and is headquartered in South Jordan, Utah.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-01 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

+5.71 (+1.00%)

USD64.79B 50.65 39.69
HOLX Hologic, Inc

-0.03 (-0.05%)

USD13.86B 32.64 22.48
MASI Masimo Corporation

+1.71 (+0.75%)

USD12.02B 61.25 42.75
XRAY DENTSPLY SIRONA Inc

+0.89 (+2.02%)

USD9.39B 118.51 21.49
RGEN Repligen Corporation

+0.58 (+0.47%)

USD5.92B 264.31 99.47
ICUI ICU Medical, Inc

-1.76 (-0.95%)

USD3.60B 44.56 18.28
IRTC iRhythm Technologies, Inc

-1.22 (-1.05%)

USD3.08B N/A N/A
STAA STAAR Surgical Company

-1.11 (-1.80%)

USD2.51B 174.93 163.22
ATRC AtriCure, Inc

+0.32 (+0.71%)

USD1.78B N/A N/A
LMNX Luminex Corporation

-0.51 (-1.57%)

USD1.34B 120.72 59.28

ETFs Containing MMSI

Symbol Name Weight Mer Price(Change) Market Cap
PSCH Invesco S&P SmallCap Heal.. 2.97 % 0.29 %

+0.04 (+0.03%)

USD0.40B
XHE SPDR S&P Health Care Equi.. 2.42 % 0.35 %

+0.50 (+0.56%)

USD0.53B
SLYV SPDR S&P 600 Small Cap Va.. 0.82 % 0.15 %

-0.95 (-1.93%)

USD2.15B
VIOV Vanguard S&P Small-Cap 60.. 0.81 % 0.15 %

-2.20 (-2.10%)

USD0.45B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 44.81% 88% B+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.81% 88% B+ 86% B
Trailing 12 Months  
Capital Gain -21.66% 29% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.66% 26% F 35% F
Trailing 5 Years  
Capital Gain 112.25% 67% D+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 112.25% 67% D+ 84% B
Average Annual (5 Year Horizon)  
Capital Gain 24.71% 66% D 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.71% 66% D 86% B
Risk Return Profile  
Volatility (Standard Deviation) 42.92% 59% F 30% F
Risk Adjusted Return 57.56% 72% C- 80% B-
Market Capitalization 2.34B 75% C 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 379.20 9% F 3% F
Price/Book Ratio 2.49 72% C- 46% F
Price / Cash Flow Ratio 30.04 38% F 9% F
EV/EBITDA 25.15 57% F 24% F
Management Effectiveness  
Return on Equity -0.42% 53% F 50% F
Return on Invested Capital 3.15% 66% D 53% F
Return on Assets 1.97% 59% F 67% D+
Debt to Equity Ratio 45.47% 38% F 47% F
Technical Ratios  
Short Ratio 9.95 19% F 8% F
Short Percent 11.24% 13% F 19% F
Beta 1.12 50% F 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector